Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. increased its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 50.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,000,000 shares of the company’s stock after purchasing an additional 1,000,000 shares during the quarter. Adage Capital Partners GP L.L.C. owned 5.56% of Fulcrum Therapeutics worth $14,100,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Bank of New York Mellon Corp increased its position in shares of Fulcrum Therapeutics by 2.3% during the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company’s stock worth $667,000 after purchasing an additional 3,126 shares during the last quarter. American Century Companies Inc. increased its position in shares of Fulcrum Therapeutics by 5.9% during the 4th quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock worth $567,000 after purchasing an additional 6,770 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Fulcrum Therapeutics by 34.4% during the 4th quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock worth $161,000 after purchasing an additional 8,761 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Fulcrum Therapeutics by 74.9% during the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company’s stock worth $143,000 after purchasing an additional 13,057 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Fulcrum Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock worth $4,716,000 after purchasing an additional 13,485 shares during the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock opened at $3.53 on Monday. The business has a 50-day moving average of $3.14 and a 200 day moving average of $3.61. The stock has a market capitalization of $190.55 million, a price-to-earnings ratio of -11.39 and a beta of 2.13. Fulcrum Therapeutics, Inc. has a 12 month low of $2.32 and a 12 month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). Equities research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.63.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.